Corcept’s Voluntary Central Distribution Helps Korlym Evade REMS
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA required no REMS, though Korlym (mifepristone), also known as RU-486, will carry a boxed warning that the therapy for Cushing’s syndrome will terminate pregnancy; Corcept has set up distribution through a central pharmacy.